Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Lead Pharma discovers and develops innovative small-molecule drugs for the treatment of autoimmune diseases and cancer.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Nov Metaphora Co., Ltd. is a company that develops and sells new drugs related to metabolic disease, which is the biggest threat of healthy life due to population aging and changes in eating habits, As a company, they expect the company to achieve 1) growth potential and profitability in the market for metabolic disease treatment products, 2) alternative antidiabetic agents with improved antidiabetic efficacy (insulin resistance improvement) due to the concentration of simple blood glucose control functions in existing diabetes drugs and reports of side effects of existing insulin sensitivity enhancers The need for development 3) One of the world's leading research institutes in the field of metabolic diseases, it has developed into a global pharmaceutical company by commercializing the research results and original technology acquired through cooperation with the VA Institute (Department of Veterans Affairs, Greater Los Angeles Healthcare System) Has been established to.

Shanghai Yibien Gene Technology Co., Ltd., established on 2015-11-02, The scope of business includes engaging in genetic technology,Biological Technology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Instrumentation,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Laboratory equipment and consumables,Sales of computer software, hardware and auxiliary equipment,Medical device management,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Shanghai Yibien Biotechnology Co., Ltd., established on 2017-03-23, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Biological Technology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer,Technology development in the field of genetic technology(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Production of Class I Medical Devices,Sales of company-produced products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. is a South Korean company located in Seoul specializing in pharmaceutical preparations. It was founded in 2016. Seon-Wook Hwang has been the CEO since the inception date. NovMetaHealth Co. Ltd. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million.

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

The Kyungpook National University Hospital is located in Daegu, South Korea. It was derived from the DaeGuDongIn Hospital which had opened in 1907. It has played as centered hospital of Gyeongsangbuk-do. As 1952 Kyungpook National University is established, it is following to the Kyungpook National University Hospitals. It is known to Korean as important general hospitals.

Shandong New Medical Research Institute of Integrated Traditional Chinese and Western Medicine Co., Ltd., established on 2008-07-18, Business scope includes general items:Human stem cell technology development and application;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Research and development of bio-based materials technology;Sales of bio-based materials;Manufacturing of bio-based materials;New material technology promotion service;Cosmetics Wholesale;Cosmetics Retail;Production of Class I Medical Devices;Health Consulting Services(Does not include medical services)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Health food sales;Production of Class II Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Hainan Yonghe Biotechnology Co., Ltd., established on 2017-12-25, Business scope includes aquaculture technology development,shrimp,fish,Crab Seedling Breeding,Sales,agricultural products,Aquatic product acquisition,processing,save,refrigeration,transportation,Sales;fry,fish eggs,feed,Dried Aquatic Products,Aquatic medicine,Aquaculture Equipment,Wholesale and retail of prepackaged food;Import and export,Catering Services.(General operating items self-management,Licensed business projects are operated on the basis of relevant licenses or approval documents)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ.

Guang Dong Yue Qun Hai Yang Sheng Wu Ke Ji Gu Fen You Xian Gong Si, established on 2001-12-04, The scope of business includes research and development of aquatic animal bait;feed,Premix,additive,Animal Nutrition and Health Products,water conditioner,Production of Microbial Agents(The above projects are operated by branches with licenses)and technology development,Technical Services,technical consulting,Sales;Aquaculture,Processing and Technology Development,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents